Latest news
Our Portfolio Company, Jounce Therapeutics, Announced Pricing of Initial Public Offering
Pharmstandard International Represented by Inbio Ventures Participated in Series B Financing of Neon Therapeutics
Pharmstandard International S.A. Represented by Inbio Ventures Leads a $20M Syndicated Series C Financing in Avelas Biosciences